Copies affect Leo Pharma’s US operations
According to Leo Pharma, it could cost the Danish pharmaceutical company up to half a billion DKK over the next six months that generic copies of the psoriasis ointment Dovonex has hit the US market. The company is currently working on a solution to minimize the loss.
af LEONORA BECK
Leo Pharma should be prepared to accept a substantial dip in earnings from the company’s psoriasis ointment Dovonex. After the generics company Sandoz, owned by Swiss company Novartis, launched a copy of the ointment on the US market in August, the Danish pharmaceutical company stands to lose up to half a billion DKK in turnover, according to Danish business daily Børsen.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
